- Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation Regeneron
- FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC The American Journal of Managed Care® (AJMC®)
- FDA Approves Libtayo for Cutaneous Squamous Cell Carcinoma Treatment CUREtoday.com
- Regeneron stock rises after FDA approves Libtayo for high-risk skin cancer Investing.com
- FDA Approves Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma Oncology Nursing News
Balance
- Psionic Storm damage was reduced from 140 to 110 over 6 seconds (23.3 DPS > 18.3 DPS).
- Broodlord speed reduced from 2.62 to 2.42.
- Ghost HP increased from…